Congress: 119 · Status: active · Israel/Palestine classification: pro-Israel
Data (JSON) — machine-readable record of this bill (identifiers, sponsor, classification, actions, and the member-by-member vote breakdown).
Official record on Congress.gov — full text, actions, and cosponsor history for HR 661.
Sponsor: Buchanan, Vern (R-Florida)
Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 or the MIRACLE Medical Technology Act of 2025 This bill requires the Department of Health and Human Services (HHS) to implement a program for the United States and Israel to collaborate on developing and delivering health care products and services. The program must include coordinated activities in specified areas, including research and development, use of innovative technology, intellectual property protection, regulatory harmonization, disease prevention, and biological product manufacturing. The bill authorizes HHS to establish a joint United States-Israel Health Care Collaboration Center in the United States to leverage existing expertise for advancing the program’s purposes.
The bill requires the Department of Health and Human Services to create a formal U.S.-Israel partnership program for developing medical technology and healthcare products. It authorizes establishing a joint research center in the U.S. to coordinate work in areas like drug development, manufacturing, disease prevention, and intellectual property protection between the two countries.
This locks in institutional medical research collaboration with Israel at the federal level, potentially affecting which foreign research partnerships receive U.S. government resources and attention. It's a non-binding framework rather than direct funding, but signals congressional prioritization of Israel ties in the healthcare sector.